Stifel Financial Corp Has $742,000 Holdings in VanEck Pharmaceutical ETF (NASDAQ:PPH)

Stifel Financial Corp lifted its holdings in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 13.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,810 shares of the company’s stock after buying an additional 924 shares during the quarter. Stifel Financial Corp owned about 0.11% of VanEck Pharmaceutical ETF worth $742,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of PPH. Miller Investment Management LP grew its stake in shares of VanEck Pharmaceutical ETF by 13.4% during the third quarter. Miller Investment Management LP now owns 207,535 shares of the company’s stock worth $19,722,000 after purchasing an additional 24,446 shares during the period. Beck Capital Management LLC boosted its holdings in VanEck Pharmaceutical ETF by 5.2% during the third quarter. Beck Capital Management LLC now owns 22,383 shares of the company’s stock worth $2,127,000 after buying an additional 1,109 shares during the last quarter. Townsquare Capital LLC boosted its holdings in VanEck Pharmaceutical ETF by 3.8% during the third quarter. Townsquare Capital LLC now owns 3,519 shares of the company’s stock worth $334,000 after buying an additional 130 shares during the last quarter. FMR LLC increased its stake in shares of VanEck Pharmaceutical ETF by 12.5% in the 3rd quarter. FMR LLC now owns 1,905 shares of the company’s stock valued at $181,000 after acquiring an additional 212 shares during the last quarter. Finally, Bank of Montreal Can increased its stake in shares of VanEck Pharmaceutical ETF by 43.6% in the 3rd quarter. Bank of Montreal Can now owns 21,640 shares of the company’s stock valued at $2,052,000 after acquiring an additional 6,570 shares during the last quarter.

VanEck Pharmaceutical ETF Price Performance

VanEck Pharmaceutical ETF stock opened at $87.70 on Wednesday. The firm has a market capitalization of $648.10 million, a price-to-earnings ratio of 21.04 and a beta of 0.72. The company’s 50 day simple moving average is $89.96 and its 200 day simple moving average is $92.83. VanEck Pharmaceutical ETF has a fifty-two week low of $80.57 and a fifty-two week high of $99.51.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.